Gazes Cardiac Research Institute
Founded in 1987, the Institute brings together a diverse group of investigators interested in fundamental cardiovascular research and in the translation of basic scientific discoveries to clinical practice.
The Institute currently is composed of six laboratories led by Drs. Bradshaw, Kuppuswamy, McDermott, Menick, O’Brien and Zile, each dedicated to understanding the biology of heart disease at its molecular level to allow for the successful development of new therapies. The Institute has an illustrious history of discovery including the identification of gene regulatory networks, key pathways, and molecular factors which contribute to heart disease and the discovery of new prognostic indicators which will allow for the early detection and treatment of heart disease. The Institute has had a long history of outstanding funding from the NIH, VA and American Heart Association. In addition, the Institute has one of the longest funded Ruth L. Kirschstein National Research Service Award Training Grants from the NIH. This recognizes the Gazes Institute’s well documented history of training some of Americas most promising scientists, many who have gone on to careers as clinical and basic scientists in cardiovascular research including the Chief of Cardiology for Washington University, and recent trainees who are now faculty members at the University of Cincinnati School of Medicine, University of Alabama School of Medicine, and University of Colorado. Some have gone into the private sector and serve as directors of research and development at biotech companies.
The Institute has a unique collaboration between basic scientists and clinical cardiologists. Because it is adjacent to MUSC’s new heart hospital, Ashley River Tower, it affords the physicians the opportunity to “connect” the research with their own clinical experiences. It also underscores the urgency of discovering therapies for some untreatable cardiac disease, and new therapies to supplant those with limited effectiveness.